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Is birthweight associated with total and
aggressive/lethal prostate cancer risks?
A systematic review and meta-analysis
Cindy Ke Zhou*,1, Siobhan Sutcliffe2, Judith Welsh3, Karen Mackinnon4, Diana Kuh4, Rebecca Hardy4 and
Michael B Cook1
1

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NIH, DHHS, 9609 Medical
Center Drive, MSC 9774, Bethesda, MD 20892-9774, USA; 2Division of Public Health Sciences and the Siteman Cancer Center,
Department of Surgery, Washington University School of Medicine, St Louis, MO, USA; 3NIH Library, National Institutes of Health,
Bethesda, MD, USA and 4Medical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK
Background: It has been hypothesised that intrauterine exposures are important for subsequent prostate cancer risk. Prior
epidemiological studies have used birthweight as a proxy of cumulative intrauterine exposures to test this hypothesis, but results
have been inconsistent partly because of limited statistical power.
Methods: We investigated birthweight in relation to prostate cancer in the Medical Research Council (MRC) National Survey of
Health and Development (NSHD) using Cox proportional hazards models. We then conducted a meta-analysis of birthweight in
relation to total and aggressive/lethal prostate cancer risks, combining results from the NSHD analysis with 13 additional studies
on this relationship identified from a systematic search in four major scientific literature databases through January 2015.
Results: Random-effects models found that per kg increase in birthweight was positively associated with total (OR ¼ 1.02, 95%
confidence interval (95% CI) ¼ 1.00, 1.05; I2 ¼ 13%) and aggressive/lethal prostate cancer (OR ¼ 1.08, 95% CI ¼ 0.99, 1.19; I2 ¼ 40%).
Sensitivity analyses restricted to studies with birthweight extracted from medical records demonstrated stronger positive
associations with total (OR ¼ 1.11, 95% CI ¼ 1.03, 1.19; I2 ¼ 0%) and aggressive/lethal (OR ¼ 1.37, 95% CI ¼ 1.09, 1.74; I2 ¼ 0%)
prostate cancer. These studies heavily overlapped with those based in Nordic countries.
Conclusions: This study provides evidence that heavier birthweight may be associated with modest increased risks of total and
aggressive/lethal prostate cancer, which supports the hypothesis that intrauterine exposures may be related to subsequent
prostate cancer risks.

Prostate cancer is a significant public health burden and a major
cause of morbidity and mortality among men worldwide. Few risk
factors have been established for prostate cancer including
advancing age, African ancestry, a family history of this
malignancy and certain genetic polymorphisms (Al Olama et al,
2014). This may be partly owing to the fact that a majority of
studies have focused on mid- to later-life exposures, and therefore
may have missed putative aetiologically relevant time-windows,
specifically early developmental stages of the prostate gland

(Sutcliffe and Colditz, 2013). It has been hypothesised that
intrauterine exposures may contribute to subsequent increased
risk of prostate cancer (Ekbom, 1998), given that the hormonal and
metabolic environment during pregnancy influences the physiological development of the prostate gland and may modulate
hormonal sensitivity and prostate cancer risks in adult men
(Ross and Henderson, 1994; Shibata and Minn, 2000). Although
the biologic mechanisms underpinning a possible in utero origin of
prostate cancer are not fully understood, intrauterine sex steroid
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hormones, insulin-like growth factors (IGFs) and elevated number
of fetal stem cells (‘stem cell burden’ hypothesis; Ekbom, 1998)
have been suggested to have important roles.
Direct epidemiological evidence linking intrauterine hormones
and increased stem cell numbers to prostate cancer risk is sparse,
likely because of the long latency period of tumour development
and the challenge of accounting for changes in environmental
factors after birth. Therefore, prior epidemiological studies have
used birthweight as a proxy for cumulative intrauterine exposures
for multiple chronic disease outcomes (Kuh and Ben-Shlomo,
2004). For example, birthweight has been extensively studied in
relation to breast cancer and a recent meta-analysis suggested a
positive dose–response relationship (dos Santos Silva et al, 2008).
In relation to prostate cancer – another hormonally related
malignancy – an early ecologic study demonstrated that mortality
rates were positively correlated with country-level birthweight
(Lawson, 1998). However, results to date from epidemiological
studies of birthweight and prostate cancer risks have not
consistently endorsed this relationship, partly because of insufficient statistical power, especially for aggressive/lethal prostate
cancers, which are of greatest clinical relevance. Therefore, we
performed a cohort analysis using the Medical Research Council
(MRC) National Survey of Health and Development (NSHD),
which extracted birthweight from medical records within a few
weeks of delivery in 1946 and has subsequently accumulated nearly
70 years of follow-up. In addition, to provide a comprehensive
assessment of birthweight in relation to total and aggressive/lethal
prostate cancer risks, we conducted a systematic review and metaanalysis, combining results from our smaller NSHD analysis with
those prior studies identified from systematic review.
MATERIALS AND METHODS

National Survey of Health and Development. We performed a
cohort analysis in the NSHD birth cohort. A detailed description of
this birth cohort has been published previously (Wadsworth et al,
2006). In brief, this cohort is a socially stratified and representative
sample (N ¼ 5362) of single live births in England, Scotland or
Wales born in March 1946 and followed up ever since. Birthweight
data were extracted from medical records within a few weeks of
delivery. Characteristics of cohort members and their parents have
been prospectively collected at follow-ups throughout life. Cohort
members have been flagged on the National Health Service Central
Register since 1971 (at the age of 25 years) for notification of
cancer diagnoses, deaths and emigrations. We used Cox proportional hazards models with age as the underlying time scale to
estimate hazard ratio (HRs) and 95% confidence intervals (CIs) of
continuous (per kg) and categorical birthweight (o3000, 3000–
3499, 3500–3999 and X4000 g) in relation to total prostate cancer.
Follow-up of this analysis started at the age of 25 years when
cancer register data became available, and continued until prostate
cancer diagnosis, death, emigration or age 67 years (i.e., until
November 2014, the most recent date of available cancer registry
data), whichever occurred earlier. We included 2791 men in this
analysis, after excluding 2547 females, 17 men without birthweight
information and 7 without follow-up information.
Literature search. To complement the NSHD analysis and
increase the statistical power, we also conducted a systematic
review on the relationship between birthweight and prostate cancer
risks. Four major scientific literature databases (PubMed (National
Centre for Biotechnology Information, US National Library
of Medicine, Bethesda, MD, USA), EMBASE (Elsevier BV,
Amsterdam, The Netherlands), Scopus (Elsevier BV), Web of Science
(Thomson Reuters, New York, NY, USA)) were systematically searched
through January 2015 by a trained clinical informationist (JW).
2
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No date or language restrictions were applied. Search terms
incorporated a wide array of variables for, or related to, birthweight
and prostate cancer or cancer in general. Search strategies are
available from the authors on request. Two reviewers (CKZ and
MBC) independently assessed titles, abstracts and keywords to
select potentially relevant studies from retrieved references.
Discordant selections were resolved by consensus. The full text
of any original contribution that indicated a potential to contain
data on birthweight and prostate cancer, or of any review on
prostate cancer aetiology, was retrieved. Bibliographies of retrieved
full-text articles were also reviewed to identify references that may
have been missed or absent from the databases used. We contacted
corresponding authors for additional data if their publications did
not present adequate information necessary for meta-analysis.
References were compiled and managed using Endnote X7. To be
included in this meta-analysis, a published study had to fulfill the
following criteria: (1) study populations were born as singletons;
(2) have at least 20 cases and 20 controls in the analysis; (3) used a
cohort or case–control study design; and (4) provided risk
estimates with 95% CIs per unit change in birthweight, or
tabulated counts of cases and controls by birthweight category to
allow for log-linear coefficients and standard errors to be estimated
using methods described previously (Chene and Thompson, 1996).
When multiple reports were published with substantial geotemporal overlap in the base population, we included the most recent
or best-powered publication. Two reviewers (CKZ and MBC)
independently extracted data from selected articles according to a
standard form created a priori for this study. Differences were
resolved by consensus.
Meta-analysis. For studies reporting results with categorical
birthweight, we calculated individual unadjusted log odds ratios
(ORs) per kg increase in birthweight and their standard errors
using tabulated counts of cases and controls by birthweight
category via methods described previously (Chene and Thompson,
1996). For studies reporting results with continuous birthweight,
we back-calculated log risk estimates per kg and their standard
errors using reported estimates and their 95% CIs. Unadjusted or
minimally adjusted risk estimates were preferred over maximally
adjusted estimates, given the fact that putative confounding factors
showed little or no effect on estimates attained for the relationship
between birthweight and prostate cancer risks in prior studies. This
has the additional benefit of reducing excess heterogeneity
attributable to different model specifications used in published
studies. We pooled study-specific risk estimates using a randomeffects meta-analytic model, and tested for between-study heterogeneity in risk estimates using a w2 test based on the Q statistic, as
well as the I2 statistic and its 95% uncertainty interval (95% UI). To
evaluate publication bias, we visually inspected the symmetry of
funnel plots and quantitatively tested the bias using Begg’s rank
correlation test and Egger’s linear regression test. To evaluate the
influence of individual studies on the summary estimates, we
performed influence analyses by leaving out one study at a time
and re-estimating the summary estimates. We also performed
meta-regression by separately including study-level covariates,
such as birthweight source (medical records vs reported), country
(Nordic vs non-Nordic), design (cohort/nested case–control vs
population-based case–control), mid-birth year (p1945 vs 41945;
The World War II ends in 1945), mean/median age at diagnosis
(p65 vs 465 years) and adjustment status (no/minimal vs
maximum), which were specified a priori. Finally, analyses were
also conducted using fixed-effects models for the purpose of
comparison and comprehensiveness. Meta-analyses were conducted separately for total and aggressive/lethal prostate cancers.
All statistical analyses were performed using Stata version 13 (Stata
Corp., College Station, TX, USA). Two-sided P-valueso0.05 were
considered statistically significant.
www.bjcancer.com | DOI:10.1038/bjc.2016.38
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RESULTS

NSHD results. Of the 2791 men in the NSHD birth cohort, 81
were diagnosed with prostate cancer through November 2014, of
which 24 (30%) were diagnosed at ages younger than 60 years.
Characteristics by event status are shown in Supplementary
Table 1. Generally, these characteristics were evenly distributed
by event status, except that fathers and maternal grandfathers of
prostate cancer cases were more likely to have non-manual jobs,
and mothers were more likely to have higher education compared
with those of controls. Hazard ratios and 95% CIs estimated
from Cox proportional hazards models are shown in
Supplementary Table 2. In this NSHD analysis, neither continuous
(ORper kg increase ¼ 0.84, 95% CI ¼ 0.56, 1.27) nor categorical
(OR3000–3499 vs o3000 g ¼ 1.03, 95% CI ¼ 0.54, 1.95; OR3500–3999 vs
o3000 g ¼ 0.98, 95% CI ¼ 0.51, 1.86; ORX4000 vs o3000 g ¼ 0.93, 95%
CI ¼ 0.42, 2.06) birthweight were significantly associated
with prostate cancer. The proportional hazards assumptions
held
with
nonsignificant
Schoenfeld
residuals
test
(Pcontinuous birthweight ¼ 0.103; Pcategorical birthweight ¼ 0.478). As
adjustment for father’s and maternal grandfather’s occupation as
well as mother’s education did not materially change the results
(Supplementary Table 2), we used unadjusted risk estimates in
subsequent meta-analysis.
Literature search and study characteristics. A flow chart for this
systematic review is shown in Figure 1. After independently
screening titles, abstracts and key words, we deemed 49 articles to
be potentially eligible and retrieved their full texts. After reviewing
the full texts and their bibliographies, we included 14 studies in
total (Ekbom et al, 1996, 2000; Boland et al, 2003; Kajantie et al,
2005; McCormack et al, 2005; Nilsen et al, 2005; Eriksson et al,
2007; Sutcliffe et al, 2007; Parent et al, 2008; Barker et al, 2012;

Lope et al, 2012; Cook et al, 2013; Gerdtsson et al, 2015) including
the NSHD analysis presented herein for qualitative and quantitative synthesis, 8 of which were cohort in design (Kajantie et al,
2005; McCormack et al, 2005; Nilsen et al, 2005; Eriksson et al,
2007; Sutcliffe et al, 2007; Barker et al, 2012; Cook et al, 2013)
including the NSHD analysis presented herein, 3 were nested case–
control (Ekbom et al, 1996, 2000; Gerdtsson et al, 2015) and 3 were
population-based case–control (Boland et al, 2003; Parent et al,
2008; Lope et al, 2012). Four of these 14 included studies used
reported birthweight (Sutcliffe et al, 2007; Parent et al, 2008; Lope
et al, 2012; Cook et al, 2013), 9 were conducted in Nordic countries
(Ekbom et al, 1996, 2000; Kajantie et al, 2005; McCormack et al,
2005; Nilsen et al, 2005; Eriksson et al, 2007; Barker et al, 2012;
Cook et al, 2013; Gerdtsson et al, 2015), and 8 reported the
association between birthweight and aggressive/lethal prostate
cancers (Ekbom et al, 1996; Kajantie et al, 2005; Nilsen et al, 2005;
Eriksson et al, 2007; Sutcliffe et al, 2007; Parent et al, 2008; Lope
et al, 2012; Gerdtsson et al, 2015). Among those eight studies with
subtype results, the Finnish study by Kajantie et al (2005) was the
only study that did not report the association with total incident
prostate cancer. Among excluded studies, five overlapped with the
base populations of included studies (Tibblin et al, 1995; Platz et al,
1998; Ahlgren et al, 2007; Lahmann et al, 2010, 2012).
Characteristics of included studies on birthweight in relation to
prostate cancer risks are shown in Table 1.
Meta-analysis
Total prostate cancer. We pooled risk estimates from 13 studies
for the risk of total prostate cancer per kg increase in birthweight
using a random-effects model, and found that birthweight was
associated with a small increased risk of the outcome (OR ¼ 1.02,
95% CI ¼ 1.00, 1.05; P ¼ 0.045) (Figure 2). Publication bias was
unlikely given the nonsignificant Begg’s (P ¼ 0.583) and Egger’s

901 records identified through
literature search

355 records after duplicates removed

355 records screened

306 records excluded

49 full-text articles
assessed for eligibility
Excluded:
37 lack of birthweight or
prostate cancer data
1 twin study
5 with substantial overlap
with selected studies

7 additional
records identified
in citations

1 NSHD analysis
presented in this
manuscript
14 studies included in
qualitative synthesis

14 studies included in
quantitative synthesis
(meta-analysis)

Figure 1. Flow chart for systematic review.
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US

Sweden,
Gothenburg

Finland

Denmark,
Copenhagen
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Sweden,
Uppsala

Sweden,
Stockholm

Sweden,
Malmo

US,
Minnesota

Canada,
Montreal

Spain

Publication Study
year
country

First
author

Minnesota birth
certificate

Self-reported at
enrollment

Self-reported at
enrollment

Birth weight
source

Cohort

Cohort

Cohort

Cohort

Cohort

1913

1934–1944

1936–1969

1946

1874–1946

1889–1941

1921–1949

1941–1959

1994–2002

1963–1998

1971–2006

1976–2010

1971–2014

1958–1994

1958–1994

1991–2006

1988–1995

2005–2009

2008–2015

B1923–1973

1930–1968

Year of
recruitment/
Dx

Birth cohort

Self-reported in 1994 1911–1946

Obstetrics records

Birth records

Reported by
parent(s) at first
school health
examination

Birth record

Nested case–control Standardised
hospital maternity
charts

Nested case–control Standardised
hospital chart

Nested case–control Hospital chart

Population-based
case–control

Population-based
case–control

Population-based
case–control

Study design

20 266

1436

6975

93 625

2791

941

2714

4348

950

3278

1537

Sample
size

Table 1. Characteristics of included studies on birthweight in relation to prostate cancer risks (N ¼ 14)

68.0 (median)

51.1 (mean)

65.0 (median)

B66.0 (mean)

Age at Dx

PCa (950);
metastasised PCa
(69)

o5.5, 5.5–9.0,
49 lbs

o2.5, 2.5–3.9,
43.9 kg

Exposure
Measure

61 (mean)

68 (mean)

NA

NA

NA

i

Adjusted for the birth
year and age

Pper g; p3000,
3001–4249, X4250
g

o5.5, 5.5–6.9, 7–
Unadjusted
8.4, 8.5–9.9, X10 lbs

Unadjusted

Adjusted for birth year
and age

Matched by the birth
year. Adjusted for age

Matched by birth year
and age at dx. Adjusted
for maternal age,
socioeconomic status,
parity, pre-eclampsia/
eclampsia, prematurity,
age at menarche and
neonatal jaundice

Matched by birth year
and age at dx. Adjusted
for maternal age,
socioeconomic status,
parity, pre-eclampsia/
eclampsia and
gestational age

Per kg

Per kg

Per g

Per g

B65 (mean)

NA

Matched by birth year

Matched by age at dx

Matched by age at dx

Adjustment for
Covariates

Per g; p3000, 3001– Matched by birth year
3500, 3501–4000,
and age at dxf
44000 g

Per kg; o3000,
3000–3499, 3500–
3999, X4000 g

691

1880

3516

Driver’s license p3000, 3001–3500,
(374); Birth
3501–4000,
certificate listing 44000 g
(384)

1657

324

Control
number

B60.5 (median) NA

PCa (120); PCa death 74.2 (mean)
(68)

PCa (221);
PCa death (5)

PCa (1699)

PCa (81)

PCa (250); PCa death 70.5 (mean)
(80)

PCa (834)

PCa (832);
metastasised PCa
(237);

PCa (192)

PCa (1621);
aggressived PCa
(440)

PCa (695);
aggressiveb PCa
(371)

Case number
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g

f

Additional data from personal communications with Dr David Ulmert from Memorial Sloan-Kettering Cancer Center, USA.
Matching may be incomplete, given that men without birth weight information were excluded after matching and that the missing distributions may be different between cases and controls.
The analysis of MRC National Survey of Health and Development (NSHD) data, herein.
h
Additional data from personal communications with Drs Johan G Erikson from University of Helsinki, Finland and Clive Osmond from University of Southampton, UK.
i
Results presented in the abstract were age-adjusted.
j
Age at prostate cancer death.
k
Age at diagnosis of all male cancers.
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e

Abbreviations: dx ¼ diagnosis; g ¼ gram; kg ¼ kilogram; MRC ¼ Medical Research Council; PCa ¼ prostate cancer; NA ¼ not applicable; NSHD ¼ National Survey of Health and Development; s.d. ¼ standard deviation; UK ¼ United Kingdom; USA ¼ United States of
America. The table is sorted by study design and reverse chronological order of publication year.
a
Additional data from personal communications with Dr Virginia Lope from Carlos III Institute of Health, Spain.
b
Aggressive defined as Gleason score X7.
c
Additional data from personal communications with Marie-Elise Parent from INRS-Institut Armand-Frappier, Canada.
d
Aggressive defined as Gleason score X7 with primary pattern ¼ 4.

Unadjusted
o3260, 3260–3590,
3595–3920,
X3925 g
NA
Birth records
Norway
2005
Nilsen

Cohort

1920–1958

1961–2001

19 681

PCa (159);
metastasised PCa
(33)

65.0 (median)

Adjusted for age and
gestational age
NA
Obstetric notes
Sweden,
Uppsala
2005
McCormack

Cohort

1915–1929

1960 –2001

5820

PCa (405)

68.4k (median)

Per kg

Adjusted for birth years
and gestational age
Per kg
NA
65.2j (mean)
Birth record
Finland
2005
Kajantie

Cohort

1924–1944

1971–1998

7203

PCa death (22)

Control
number
Birth weight
source
Study design
Publication Study
year
country
First
author

Table 1. ( Continued )

Birth cohort

Year of
recruitment/
Dx

Sample
size

Case number

Age at Dx

Exposure
Measure

Adjustment for
Covariates

Birthweight and prostate cancer

(P ¼ 0.202) tests, although the funnel plot appeared slightly
asymmetric (Supplementary Figure 1). Omission of one study at
a time did not materially change the summary risk estimate
(Supplementary Table 3). In particular, when Sutcliffe et al (2007)
or Parent et al (2008) – which had the greatest weights – were
excluded, the summary risk estimates did not deviate from the
overall risk estimate. Subgroup analyses of study-level variables
showed that birthweight source (P ¼ 0.014) and country
(P ¼ 0.005) may partially explain the small amount of betweenstudy heterogeneity detected, with higher summary risk estimates
for studies that used medical records to ascertain birthweight
(ORper kg increase ¼ 1.11, 95% CI ¼ 1.03, 1.19) and studies in Nordic
countries (ORper kg increase ¼ 1.10, 95% CI ¼ 1.04, 1.16) (Table 2).
Seven of the nine studies that used medical records to ascertain
birthweight were based in Nordic countries. Given the heterogeneity test was not statistically significant (P ¼ 0.312) with
I2 ¼ 13% (95% UI ¼ 0%, 52%), we performed sensitivity analyses
using fixed-effects models, which provided similar overall (ORper kg
increase ¼ 1.02, 95% CI ¼ 1.00, 1.03; P ¼ 0.028) and subgroup
summary estimates (Supplementary Table 4).
Aggressive/lethal prostate cancer. We separately conducted a
meta-analysis using a random-effects model of eight studies that
provided birthweight in relation to aggressive/lethal prostate
cancer risk. We found that per kg increase in birthweight seemed
to be associated with an 8% increased risk of aggressive/lethal
disease (OR ¼ 1.08, 95% CI ¼ 0.99, 1.18; P ¼ 0.076), although the
association was not statistically significant (Figure 3). Publication
bias was suggested by the asymmetry of the funnel plot
(Supplementary Figure 2), yet objective judgment is difficult with
only eight studies and Begg’s (P ¼ 0.266) and Egger’s (P ¼ 0.054)
tests were not statistically significant. In influence analyses, the
study by Parent et al (2008) was found to have an influence on the
summary estimate, as the estimate became statistically significant
and increased by 6% (OR ¼ 1.14, 95% CI ¼ 1.01, 1.28) once such
study was removed (Supplementary Table 3). Of the eight studies
included in this analysis, all Nordic studies had retrieved
birthweight information from medical records, whereas all nonNordic studies used reported birthweight. Subgroup analyses of the
study-level variables showed that the moderate between-study
heterogeneity (I2 ¼ 40%, 95% UI ¼ 0%, 73%; P ¼ 0.115) may be
explained by birthweight source/study country (P ¼ 0.020) and
study design (P ¼ 0.012), with higher summary estimates for
aggressive/lethal prostate cancer when restricted to Nordic studies
that used medical record birthweight (ORper kg increase ¼ 1.37,
95% CI ¼ 1.09, 1.74), or studies in cohort/nested case–control
designs (ORper kg increase ¼ 1.14, 95% CI ¼ 1.05, 1.24) (Table 2).
For comparison and comprehensiveness, we performed
fixed-effects meta-analysis, in which we found a slightly
smaller but statistically significant overall summary result
(ORper kg increase ¼ 1.04, 95% CI ¼ 1.00, 1.08; P ¼ 0.026) as well as
consistent subgroup results (Supplementary Table 4).
DISCUSSION

We did not find a statistically significant association between
birthweight and total prostate cancer risk in the NSHD birth
cohort, which may be because of the small number of events. Also,
we did not have information on tumour characteristics to evaluate
the association with aggressive/lethal prostate cancer in this birth
cohort. However, our systematic review and meta-analysis suggests
that greater birthweight is associated with small increased risks of
total and aggressive/lethal prostate cancer. We detected a small
amount of heterogeneity for total prostate cancer (I2 ¼ 13%) but a
moderate amount for aggressive/lethal disease (I2 ¼ 40%). The
associations of birthweight with total and aggressive/lethal prostate
5
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Publication Study
year
country

ES (95% Cl)

%
Weight

Medical records
Ekbom

1996

Sweden, Uppsala

1.08 (0.77, 1.51)

0.50

Ekbom

2000

Sweden, stockholm

0.98 (0.81, 1.19)

1.50

Boland

2003

US, Minnesota

0.91 (0.66, 1.25)

0.54

McCormack

2005

Sweden, Uppsala

1.17 (1.05, 1.31)

4.30

Nilsen

2005

Norway

1.11 (0.79, 1.57)

0.47

Eriksson

2007

Sweden, Gothenburg

1.24 (0.91, 1.68)

0.59

Barker

2012

Finland

1.14 (0.87, 1.50)

0.74

Gerdtsson

2015

Sweden, Malmo

1.14 (0.97, 1.33)

2.17

Zhou

2015

UK

0.84 (0.56, 1.27)

Subtotal (l 2 = 0.0%, P = 0.605)

1.11 (1.03, 1.19)

0.33
11.14

Reported
Sutcliffe

2007

US

1.01 (0.99, 1.04)

41.88

Cook

2013

Denmark, Copenhagen

1.06 (0.97, 1.15)

6.96

Lope

2015

Spain

0.94 (0.75, 1.19)

1.04

Parent

2015

Canada, Montreal

1.01 (0.98, 1.03)

38.97

Subtotal (l 2 = 0.0%, P = 0.700)

1.01 (1.00, 1.03)

88.86

Overall (l 2 = 13.2%, P = 0.312)

1.02 (1.00, 1.05)

100.00

0.5

0.67

0.83

1

1.1 1.2

1.5

2

Figure 2. Birthweight (per kg) in relation to total prostate cancer risk by birthweight source using a random-effects model (N ¼ 13).

cancer were stronger when restricted to studies that used
birthweight extracted from medical records or studies that were
based in Nordic countries.
Although our meta-analysis estimated positive associations
between birthweight and risks of total and aggressive/lethal
prostate cancer, the magnitude of these associations was modest.
However, we believe this modest magnitude is consistent with use
of a proxy measure of the intrauterine environment rather than the
possible causal exposure. Similar modest associations have also
been observed for other in utero markers and prostate cancer risk,
consistent with our findings for birthweight. For example, shorter
duration of gestation, which is associated with lower birthweight,
has been inversely associated with prostate cancer risk (Ekbom
et al, 1996), whereas higher parity (X4) and placental weight,
which are both associated with greater birthweight, have been
positively associated with prostate cancer risk (Ekbom et al, 1996,
2000). In addition, taller adult height, another marker correlated
with greater birthweight (Eide et al, 2005), was positively associated
with total (ORper 5 cm ¼ 1.04, 95% CI ¼ 1.03, 1.05) and advanced
(ORper 5 cm ¼ 1.04, 95% CI ¼ 1.02, 1.06) prostate cancer in a recent
meta-analysis (World Cancer Research Fund International, 2014).
Whether the link between birthweight and prostate cancer risks is
mediated in full or part by adult height requires further
investigation. Although birthweight is frequently used as a proxy
of intrauterine exposures, the biologic mechanisms underlying a
possible birthweight–prostate cancer association are not fully
understood. Endogenous hormones, such as sex steroid hormones
(Petridou et al, 1990; Peck et al, 2003) and IGFs (Orbak et al, 2001;
Skalkidou et al, 2002; Davidson et al, 2006), and increased fetal
stem cell burden (Strohsnitter et al, 2008; Capittini et al, 2011) in
utero – all of which have demonstrated correlations with
birthweight – have been hypothesised to modulate hormonal
sensitivity and the risk of prostate cancer in adulthood.
Maternal and fetal sex steroid hormones act in concert in
prenatal development, and homeostasis of both is essential for
subsequent prostate health. The development of the prostate gland
is androgen-dependent. Prostatic buds emerge from the urogenital
6

sinus, which expresses androgen receptors stimulated by testicular
androgens at approximately the tenth week of gestation (Cunha
et al, 1987). It has been speculated that increased testosterone
exposure in utero might reset the hypothalamic-pituitary-testicular
feedback axis, leading to increased androgen secretion later in life.
This hypothesis has been proposed to explain racial variation in
prostate cancer risk (Ross and Henderson, 1994), as higher
testosterone and oestradiol levels have been found in early
gestational blood from African American than Caucasian women
(Henderson et al, 1988; Potischman et al, 2005), higher
testosterone to sex hormone-binding globulin concentration ratios
have been found in cord blood from African American than their
Caucasian male neonates (Rohrmann et al, 2009), and higher ageadjusted free testosterone concentrations were found in healthy
adult African American men than their Caucasian counterparts in
a recent meta-analysis (Richard et al, 2014). On the other hand, as
fetal androgen levels decline and maternal oestrogen levels rise in
the third trimester, exposure to excessive oestrogens can induce
aberrant proliferation of the prostatic epithelium, which may lead
to squamous metaplasia in the fetus, although this pathological
change regresses rapidly after birth when maternal oestrogens
plummet (Ellem and Risbridger, 2009). Evidence for oestrogen
carcinogenesis has been consistently documented in rodent studies,
which have demonstrated that exposure to high-dose diethylstilbestrol and 17 b-oestradiol during development can reprogramme
the prostate gland and increase its susceptibility to carcinogenesis
with ageing (Prins and Ho, 2010).
Other hormones regulating growth and metabolism may also
have roles in subsequent prostate carcinogenesis. Insulin-like
growth factors are required for prostate gland development (Ruan
et al, 1999), and adult circulating concentrations have been
positively associated with prostate cancer risk (Rowlands et al,
2009). Moreover, IGF-1 and IGFBP-3 concentrations in cord blood
have been correlated with increased number of stem cell measures,
which may confer higher susceptibility to later malignant
transformation, and to a lesser extent, oestradiol, oestriol and
testosterone were also correlated with such (Baik et al, 2005).
www.bjcancer.com | DOI:10.1038/bjc.2016.38
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Table 2. Subgroup Analyses for birthweight (per kg) in relation to prostate cancer risks by random-effects models
Heterogeneity
No. of
studies

ORs

Source of birthweight
Medical records
Reported

9
4

1.11
1.01

1.03, 1.19
1.00, 1.03

Study country
Nordic
Other

8
5

1.10
1.01

1.04, 1.16
0.99, 1.03

Study design
Cohort/nested case–control
Population-based case–control

10
3

1.06
1.01

1.01, 1.11
0.98, 1.03

Mid-birth cohort
p1945
41945

9
4

1.03
1.03

1.00, 1.06
0.95, 1.11

Mean/median age at diagnosis
p65
465

6
7

1.01
1.06

0.99, 1.04
0.99, 1.14

Adjustment status
No/minimal
Maximum

10
3

1.03
1.05

1.00, 1.06
0.97, 1.13

Source of birthweight
Medical records
Reported

5
3

1.37
1.05

1.09, 1.74
0.97, 1.13

Study country
Nordic
Other

5
3

1.37
1.05

1.09, 1.74
0.97, 1.13

Study design
Cohort/nested case–control
Population-based case–control

6
2

1.14
1.02

1.05, 1.24
0.98, 1.06

Mid-birth cohort
p1945
41945

7
1

1.10
0.92

1.00, 1.22
0.70, 1.21

Mean/median age at diagnosis
p65
465

2
6

1.02
1.15

0.98, 1.06
0.99, 1.33

Adjustment status
No/minimal
Maximum

7
1

1.08
1.49

0.99, 1.18
0.76, 2.91

95% CIs

P-value from
meta-regression

I2

95% UIs

P-value

0
0

0, 56
0, 68

0.605
0.700

0
0

0, 47
0, 49

0.746
0.804

25
0

0, 64
0, 72

0.216
0.690

30
0

0, 67
0, 81

0.182
0.491

0
42

0, 61
0, 75

0.661
0.114

30
0

0, 66
0, 61

0.173
0.763

0
51

0, 58
0, 86

0.735
0.129

0
51

0, 58
0, 86

0.735
0.129

0
0

0, 73
NA

0.455
0.467

44
NA

0, 77
NA

0.095
NA

0
27

NA
0, 69

0.609
0.235

43
NA

0, 76
NA

0.106
NA

Total PCa
0.014

0.005

0.178

0.913

0.477

0.648

Aggressive/lethal PCa
0.020

0.020

0.012

0.265

0.291

0.358

Abbreviations: CI ¼ confidence interval; NA ¼ not applicable; OR ¼ odds ratio; PCa ¼ prostate cancer; UI ¼ uncertainty interval.

However, contrary to the expected direction of the association
based on racial variation in prostate cancer risk, one study found
that African-American neonates had lower concentrations of IGFs
in cord blood than Caucasians (Rohrmann et al, 2009). Finally,
leptin (Lai et al, 2011) and vitamin D (Eichholzer et al, 2013) cord
blood levels were also similar in African-American and Caucasian
neonates, suggesting that intrauterine exposure to these molecules
is unlikely to explain racial differences in prostate cancer risk in
adulthood.
This meta-analysis has several limitations that merit discussion.
We cannot rule out measurement error in the three studies that
used self-reported birthweight (Parent et al, 2008; Lope et al, 2012;
Sutcliffe, 2007), given the fair-to-moderate agreement between selfreported and birth certificate-ascertained birthweight in prior
validation studies (Jaworowicz et al, 2010); one cohort study that
used maternal-reported birthweight (Cook et al, 2013) may have
been subject to a lesser degree of measurement error (Adegboye
and Heitmann, 2008). The stronger association observed in the
subgroup of medical record-ascertained birthweight indirectly
supports the possible existence of measurement error. Furthermore, we cannot exclude recall bias for two of these studies that
www.bjcancer.com | DOI:10.1038/bjc.2016.38

ascertained birthweight information by self-report after prostate
cancer diagnosis in a population-based case–control design (Parent
et al, 2008; Lope et al, 2012), given that the summary estimate
significantly increased by 10% (ORper kg increase ¼ 1.14, 95%
CI ¼ 1.05, 1.24) for aggressive/lethal prostate cancer after omitting
these two studies, although the summary estimate was not
materially changed for total prostate cancer (ORper kg increase ¼ 1.05,
95% CI ¼ 1.01, 1.10; P ¼ 0.024). Measurement error and recall bias
usually attenuate associations, thus we may have underestimated
the magnitude of the relationships between birthweight and
prostate cancer risks. Second, we extracted/estimated unadjusted
or minimally adjusted risk estimates from the majority of studies
included, even though gestational age, maternal smoking, pregnancy-related and neonatal complications (e.g., pre-eclampsia/
eclampsia and jaundice), birth order/parity and maternal anthropometric measures have been hypothesised to confound
birthweight–prostate cancer associations. However, as prior studies
to assess such factors found little or no effect on estimates (Boland
et al, 2003; Nilsen et al, 2005; Eriksson et al, 2007; Zhou et al,
herein), and as adjustment status was not significant in our
subgroup analysis, we do not believe that use of minimally adjusted
7
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Study

Year

Birthweight and prostate cancer

Study
country

ES (95% Cl)

%
Weight

Medical records
Ekbom

1996

Sweden, Uppsala

1.49 (0.76, 2.91) 1.70

Kajantie

2005

Finland

2.38 (0.98, 5.80) 0.98

Nilsen

2005

Norway

1.24 (0.58, 2.64) 1.35

Eriksson

2007

Sweden, Gothenburg

1.41 (0.93, 2.13) 4.26

Sweden, Malmo

1.22 (0.83, 1.78) 4.95

Gerdtsson 2015
2

Subtotal (l = 0.0%, P = 0.735)

1.37 (1.09, 1.74) 13.24

Reported
Sutcliffe

2007

US

1.11 (1.02, 1.21) 33.62

Lope

2015

Spain

0.92 (0.70, 1.21) 8.77

Parent

2015

Canada, Montreal

1.02 (0.98, 1.06) 44.37

2

2

1.5

1
1.1
1.2

1.08 (0.99, 1.18) 100.00

0.83

Overall (l 2 = 39.5%, P = 0.115)

0.67

1.05 (0.97, 1.13) 86.76

0.5

Subtotal (l = 51.2%, P = 0.129)

Figure 3. Birthweight (per kg) in relation to aggressive/lethal prostate cancer risk by birthweight source using a random-effects model (N ¼ 8).

estimates influenced our conclusions (Table 1). Third, longitudinal
anthropometric measures, such as adult height, were only
ascertained in two of the included studies (Cook et al, 2013;
Gerdtsson et al, 2015). As these studies observed different results
for anthropometric measures, we are unable to evaluate to what
extent the effects of birthweight may be mediated by adult height.
Fourth, we cannot exclude the possibility of publication bias for the
meta-analysis on aggressive/lethal prostate cancer, given that only
eight studies presented results for this subgroup of cases. Last,
studies included in this meta-analysis were primarily conducted in
men with European ancestry, and therefore we were unable to
evaluate whether birthweight is associated with prostate cancer
risks in men with African ancestry.
In conclusion, this systematic review and meta-analysis suggests
that heavier birthweight may be associated with modest increased
risks of total and aggressive/lethal prostate cancer. Novel
approaches and longitudinal data are needed in future birth
cohorts to elucidate biological mechanisms and determine the
aetiological time windows for prostate carcinogenesis.
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